Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × eribulin × Lymphoid × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 81 Sarcoma 8 Gynecologic 4 CNS 4 Other solid neoplasm 2 Genitourinary 2 Tumor-Agnostic 1 Lymphoid 1 Head & Neck 1 Gastrointestinal 1

Conditions

Neoplasms 1 Lymphoma 1

Interventions

Cyclophosphamide 791 Rituximab 782 Etoposide 340 Vincristine 339 Doxorubicin 309 fludarabine 304 Cytarabine 301 fludarabine phosphate 279 Methotrexate 271 Prednisone 253 Dexamethasone 250 Lenalidomide 223 Filgrastim 203 Melphalan 179 Radiotherapy 160 Peripheral Blood Stem Cell Transplantation 158 Whole-Body Irradiation 152 Busulfan 146 Bendamustine Hydrochloride 144 venetoclax 142 Mycophenolic Acid 141 ibrutinib 132 Granulocyte Colony-Stimulating Factor 127 Bortezomib 121 Tacrolimus 119 obinutuzumab 109 Gemcitabine 105 Cyclosporine 98 Antilymphocyte Serum 89 Carmustine 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02082626 2020-03-10

ERIBULIN

University of Oklahoma

Phase 1 Terminated

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡